

Special Issue

Innovations in Understanding and Treating Pancreatic Diseases

Message from the Guest Editor

- Pancreatic diseases, including pancreatitis and pancreatic cancer, represent some of the most challenging conditions in gastroenterology and oncology due to their complex pathogenesis, late diagnosis, and limited therapeutic options. Despite advances in molecular and translational research, patient outcomes remain poor, especially in pancreatic ductal adenocarcinoma (PDAC), where the tumor microenvironment, immune evasion, and metastatic spread to organs like the liver play central roles.
- We welcome original research and reviews addressing topics such as the genetic and epigenetic drivers of pancreatic disease, inflammation–fibrosis–cancer transition, epithelial–mesenchymal transition (EMT), tumor microenvironment remodeling, immune regulation, and mechanisms of metastasis. Special emphasis will be given to translational and clinical studies exploring novel biomarkers, targeted therapies, immunotherapies, and innovative treatment strategies.
- By gathering contributions across disciplines—from basic science to clinical applications—this Special Issue seeks to advance our understanding of pancreatic diseases and promote the development of more effective, personalized interventions.

Guest Editor

Dr. Federica Rubbino

Laboratory of Macrophage Dynamics, IRCCS Humanitas Research Hospital, Rozzano, Italy

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/247745

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).